Johnson & Johnson Deepens Oncology And MedTech Footprint With New Approvals
unknown📝 Article Content
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination therapy for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplant. Johnson & Johnson MedTech launched NuVision Nav, described as the world's first fully integrated 4D intracardiac imaging catheter, alongside updates to its pulsed field ablation technology. Johnson & Johnson, trading at $233.1, is adding fresh catalysts to its oncology and MedTech franchises with these...
📄 Summary
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination therapy for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplant. Johnson & Johnson MedTech launched NuVision Nav, described as the world's first fully integrated 4D intracardiac imaging catheter, alongside updates to its pulsed field ablation technology. Johnson & Johnson, trading at $233.1, is adding fresh catalysts to its oncology and MedTech franchises with these...